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In the paper published in this review, Robert Leipold et al. 1 conducted a modelling analysis of the potential effect of lomitapide, on major adverse cardiovascular events and survival in homozygous familial hypercholesterolemia. This rare and life-threatening disease has been defined phenotypically on the basis of an untreated (low-density lipoprotein (LDL)-cholesterol plasma concentration of more than 13 mmol/L (>500 mg/dL), or a treated LDL-cholesterol concentration of 8 mmol/L or greater (!300 mg/dL), and the presence of cutaneous or tendon xanthomas before the age of 10 years, or the presence of elevated LDL-cholesterol levels consistent with heterozygote familial hypercholesterolemia in both parents. 2 Patients with homozygous familial hypercholesterolemia are at extremely high risk of cardiovascular disease, with severe events occurring during childhood or young adulthood if untreated. 2 From the pre-statin era, the management of homozygous familial hypercholesterolemia has evolved following the widespread availability of statins, ezetimibe, as well as lipoprotein apheresis. However, despite these treatments most patients do not reach their LDL-cholesterol targets. These patients may benefit from new therapeutic options such as proprotein convertase subtilisin-kexin type 9 (PCSK9) antibodies, lomitapide and mipomersen (microsomal transfer protein inhibitors) and cholesterol-ester transfer protein inhibitors. 2 The latter group has not yet obtained market approval. Subject to consideration of benefit/ versus risk and cost, which may differ from country to country, such pharmacotherapies may ultimately translate to improved clinical outcome for patients with this disease. Randomised studies assessing the impact of these new therapeutic options on clinical events are not feasible and might even be unethical. However, the cost of the above-mentioned new therapeutic options is also very high and it is most useful to approach by modelling their potential benefit. This is obviously important for the homozygous but also the heterozygote form in which no clinical outcome trials have yet been conducted. 3 However, we should keep in mind that homozygous hypercholesterolemia is heterogeneous in terms of LDL-cholesterol reduction upon treatment. In this respect it is important to look specifically at the benefit in the most interesting subgroup with null mutations which does not respond to PCSK9 inhibitors but has a significant decrease with lomitapide.
The modelling analysis considered cardiovascular events and effect on mortality. However, the disease represents a considerable burden for patients, not only due to cardiovascular disease but also due to physical signs and limitations together with a number of psychosocial factors, treatment-related issues and impact on the education and employment situation. 4 In addition, the cost of treatment including long-term weekly or bi-weekly apheresis is extremely high.
The model is based on LDL-cholesterol reduction. The risk of cardiovascular events is strongly related to cholesterol burden, i.e. the average exposure to cholesterol throughout life which is a function of plasma cholesterol levels and duration of exposure. 5, 6 As a causal relationship between LDL-cholesterol and cardiovascular events is well established, 7 the benefit of hypolipidemic drugs can indeed be evaluated by the average effect on plasma LDLcholesterol levels.
The modelling was based on a 38% plasma LDL-cholesterol reduction, which is, according to the authors, a conservative approach because the maximal efficacy might be associated with up to a 50% decrease of plasma LDL-cholesterol levels. When analysing effect on events and survival it is important to have long-term confirmation of the average LDL-cholesterol decrease in a real-life setting. The experience of the long-term decrease of LDL-cholesterol is limited, although very recently Blom et al. showed that among the 17 patients with homozygous hypercholesterolemia who completed week 126, LDL-cholesterol decreased from 356 AE 127 mg/dL at baseline to 189 AE 120 mg/dL at week 126, corresponding to a mean percentage change of À45.5% (95% confidence interval À61.6 to À29.4; P < 0.001). 8 However, we lack data on long-term compliance in a real-life setting.
The model was created from an observational study of 149 South African patients with homozygous familial hypercholesterolemia. Cardiovascular-related mortality hazards were derived by adjusting for general population non-cardiovascular-related mortality. For every mmol/L LDL-cholesterol reduction, relative risk reductions of 23% (mortality) and 15% (cardiovascular events) were observed. For the most robust model, baseline median survival with current treatments (LDL-cholesterol 8.7 mmol/L) was 48 years. Although patients with homozygous familial hypercholesterolemia have a similar poor prognosis among countries, it would be of interest to conduct a similar study in another country, which may have a distinct mortality pattern and/or have a replication cohort.
In the survival benefit analysis, starting lomitapide at the age of 18 years and reducing LDL-cholesterol by 3.3 mmol/L from baseline would increase life expectancy by 11.2 years and delay the time to first major cardiovascular event by 5.7 years. Analysis suggested lifetime lomitapide treatment could increase median life expectancy by 11.7 years and time to first major cardiovascular events by 6.7 years. The fact that there is a small difference in outcome when lifelong treatment is considered is counterintuitive and should not be taken as a message for late intervention. Indeed, it is well established that these children should be treated as early as possible by current approaches (lomitapide has not received market approval for children).
Finally, such an approach is an indirect evaluation of the benefit but does not assess the safety issues and as a consequence the real benefit/risk ratio of lomitapide treatment. The most common adverse event was gastrointestinal disorders, and others included liver transaminase elevation and hepatic fat accumulation. The long-term use of lomitapide was associated with an increased risk of progressing to steatohepatitis and fibrosis. 9 However, due to the limited number of patients treated, the long-term safety remains to be carefully analysed.
In conclusion, while modelling analysis is of great interest in evaluating the benefit of new drugs in orphan disease, still much needs to be explored to suggest that lomitapide is a life-saving drug in homozygous familial hypercholesterolemia.
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